SM-1

SM-1 research peptide primarily activates GLP-1 receptors (GLP-1R) on pancreatic beta cells, promoting glucose-dependent insulin secretion via increased cAMP levels, protein kinase A activation, and enhanced gene expression for insulin production. Furthermore, it inhibits glucagon release from alpha cells in a glucose-sensitive manner, suppresses hepatic gluconeogenesis, and delays gastric emptying to moderate postprandial glucose excursions. Additionally, centrally, it influences hypothalamic and brainstem regions to reduce appetite and food intake through neurotransmitter modulation and satiety signaling, while peripherally supporting lipid metabolism, reducing inflammation, and promoting mitochondrial function in models of metabolic stress. Laboratory studies, such as in vitro receptor binding assays and in vivo rodent models, reveal prolonged half-life due to structural modifications, enabling sustained GLP-1R signaling. These actions contribute to observed improvements in insulin sensitivity, weight regulation, and cardiometabolic pathways, with recent research emphasizing its reassuring profile for balanced metabolic modulation in diabetes, obesity, and related models.

• GLP-1 receptor activation and incretin pathway investigations

• Glucose-dependent insulin secretion mechanism analysis

• Appetite regulation and central nervous system signaling studie

• s Glucagon suppression and hepatic glucose output evaluations

• Gastric emptying delay and postprandial glucose control research

• Metabolic homeostasis, lipid metabolism, and anti-inflammatory pathway examinations

• Wilding JPH et al. N Engl J Med. 2021;384(11):989-1002
• Davies M et al. Lancet. 2021;397(10278):971-984
• Rubino D et al. JAMA. 2021;325(14):1414-1425
• Wadden TA et al. N Engl J Med. 2021;384(11):989-1002
• Marso SP et al. N Engl J Med. 2016;375(19):1834-1844